Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...

The deal comes as Novo Nordisk moves to become the leader ... especially oral drugs that don't require an injection. Lexicon Pharmaceuticals has been based in The Woodlands since its founding ...

Lexicon Pharmaceuticals focuses on the development ... with Lexicon’s announcement of a major licensing agreement with Novo Nordisk for the development and commercialization of its obesity ...